Короткий опис (реферат):
There was made a comprehensive examination of 71 patients with FHC and NASH and formed groups of patients: I - n = 35 with FHC and NASH receiving rosuvastatin 20 mg / day; II - n = 36 of FHC and NASH who received rosuvastatin and hepatoprotector "Hepadif" 2 capsules three times a day for 90 days. The results were evaluated on the 45th and 90th day of treatment. Results. With rosuvastatin monotherapy, a decrease in the level of LDL (p = 0.001) and an increase in HDL (p = 0.01) were detected. Transaminase activity and IL-6, CK-18 concentrations tended to decrease but were not statistically reliable. In group II the LDL level reached the target value, transaminase activity was lower (p = 0.001). IL-6 concentration decreased significantly by 28% (p = 0.01), CK-18 - by 36.8% (p = 0.003). Determination of IL-6 and CK-18 concentration has a strong positive relationship with hepatic transaminases and LDL level, so it is advisable to use IL-6 and CK-18 to select personalized therapy for patients with FHC and NASH.
